



## **H.C. WAINWRIGHT STRENGTHENS ITS FRANCHISE IN BIOTECHNOLOGY EQUITY RESEARCH**

NEW YORK, January 9, 2015 – H.C. Wainwright & Co., LLC (“HCW”) announced today that Ching-Yi Lin has joined the firm as a Managing Director in Equity Research and Senior Biotechnology Analyst.

Ms. Lin joins HCW from Stifel Financial where she was a Senior Research Associate covering the pharmaceutical sector. She has also held a variety of research and finance positions at Millennium Partners, Wachovia Securities and Credit Suisse. Her research has appeared in Barron’s, BusinessWeek and other major media. She is also an inventor and developer of technology, including medical devices, and has been awarded patents in various areas of technology. Additionally, Ms. Lin was a management consultant to various firms including Fortune 100 and venture-backed companies. She has worked in research labs and taught chemistry and technology. Ms. Lin earned an MBA from Columbia Business School where she graduated Beta Gamma Sigma (Honors), as well as a Master’s focusing in Finance from London Business School. She holds two undergraduate degrees from Indiana University: B.S. in Biology/Honors Program and B.A. in Economics with the equivalent of minors in Chemistry and Journalism.

“We are excited that Ching-Yi has decided to join the Biotechnology Research team at HCW, which already includes Andrew Fein, Reni Benjamin, Ph.D. and Swayampakula Ramakanth, Ph.D.” commented Mark Viklund, Chief Executive Officer of HCW. “Her skills will add depth to our franchise as we look to uncover value opportunities for our investors in the space. We expect to further enhance our capabilities with additional hires in 2015.”

### **About H.C. Wainwright & Co., LLC**

H.C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H.C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. H. C. Wainwright was established in 1868 and is headquartered in New York City.